retatrutide lancet Shows Metabolic Benefits in Phase 3 Studies Is Retatrutide The Next Weight-Loss

Medicaid plans cover drugs for Type 2 diabetes, like Ozempic, but prescription coverage with Medicaid varies by state

Eli Lilly announced positive topline Phase 3 results in March 2026 for a type 2 diabetes study, and multiple Phase 3 trials remain active across obesity and related conditions

When manual calculation still matters Calculators are tools, not replacements for understanding

Patients enrolled in the trial had biopsy proven NASH/borderline NASH (NAS 4) without cirrhosis (n = 283)

Although this topic is reviewed in detail by another article within this themed issue (Hlscher, 2021), we would like to briefly consider the following points